The Global Multi-omics Solution for Precision Oncology

Indivumed Services was acquired by Crown Bioscience from Indivumed GmbH in April 2023.

The original company was founded in 2002 by leading scientists with a drive to revolutionize cancer treatment through individualized therapy.

As an integrated global oncology company our experts leverage the highest quality biobank to develop a true picture of cancer. Our three divisions operate holistically with one another for the generation, characterization, and analysis of biologic samples from human cancer patients.

Indivumed Services is headquartered in Hamburg, Germany, with a US-based subsidiary in Frederick, Maryland, USA  and a global clinical network.

At Indivumed Services we are united by a shared responsibility:
using our unique expertise and skill sets to work toward individualized cancer diagnosis and treatment for every patient.


About Crown Bioscience

wr-crown-logo-2021-v1[1]Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing discovery, preclinical, and translational platforms to advance oncology and immuno-oncology.

Known for their high quality and expansive in vivo, in vitro and ex vivo preclinical models, they partner with their clients to quantify the efficacy and pharmacological profile of their drug candidate before they move into the clinic.

The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Additionally, further services available in the areas of high content imaging and a 3D Ex Vivo Patient Tissue Platform, provide greater insights into complex disease pathophysiology. A range of biomarker analysis and applied genomics services are also available to optimize therapeutic benefit.

Crown Bioscience helps to deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has 12 facilities in the US, Europe, and APAC. Find out more: